| September 28, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
|
| September 28, 2023 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employee and External collaborator
|
| September 20, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Employee
|
| September 20, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Director
|
| September 19, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employee
|
| September 19, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director
|
| September 13, 2023 |
Financial Results
|
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2023[Japanese GAAP]
|
| September 6, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy (Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and Hypertensive Cardiomyopathy)
|
| September 4, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| July 31, 2023 |
Timely Disclosure Information
|
StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Japan)
|
| July 25, 2023 |
Timely Disclosure Information
|
StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China)
|
| July 18, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| June 14, 2023 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2023[Japanese GAAP]
|
| June 1, 2023 |
IR News
|
StemRIM Announces Exhibiting at the “BIO International Convention 2023” and Participating in the “Jefferies 2023 Global Healthcare Conference New York”
|
| May 24, 2023 |
Timely Disclosure Information
|
StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide)
|
